Tumeurs endocrines gastro-entéro-pancréatiques (TE GEP). Classifications, présentations cliniques, marqueurs biologiques

  • É. Baudin
  • M. Ducreux
  • M. d’Herbomez
Chapter

Abstrait

Ce chapitre fait le point sur les classifications, les modalités du diagnostic clinique, le bilan biologique des tumeurs endocrines gastro-entéro-pancréatiques (TE GEP) non à petites cellules (1–5). Nous utiliserons le terme de «tumeur endocrine», pour définir des tumeurs bénignes ou malignes. Ce terme est consacré par la dernière classification OMS 2000 des tumeurs digestives, même s’il n’est pas reconnu par la dernière classification OMS 2004 des tumeurs pulmonaires et thymiques (6–8). Le terme «carcinoïde» se référera aux tumeurs bien différenciées. Le terme carcinome sera employé pour définir les tumeurs malignes.

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Baudin E (2007) Gastroenteropancreatic endocrine tumors: clinical characterization before therapy. Nat Clin Pract Endocrinol Metab 3: 228–39PubMedCrossRefGoogle Scholar
  2. 2.
    Modlin IM, Lye KD, Kidd M (2003) A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97: 934–59PubMedCrossRefGoogle Scholar
  3. 3.
    Quaedvlieg PF, Visser O, Lamers CB et al. (2001) Epdidemiology and survival in patients with carcinoid disease in the Netherlands: an epidemiological study with 2391 patients. Ann Oncol 12: 1295–300PubMedCrossRefGoogle Scholar
  4. 4.
    Hemminki K, Li X (2001) Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden. Int J Cancer 94: 444–8PubMedCrossRefGoogle Scholar
  5. 5.
    Skuladottir H, Hirsch FR, Hansen HH et al. (2002) Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-bases study in Denmark. Lung Cancer 37: 127–35PubMedCrossRefGoogle Scholar
  6. 6.
    Solcia E, Klöppel G, Sobin LH (2000) Histological typing of endocrine tumors. World Health Organisation International Histological Classification of Tumors. Springer, BerlinGoogle Scholar
  7. 7.
    Travis WD, Brambilla E, Müller-Hermelink, Harris C (2004) Pathology of the lung, pleura, thymus and heart. IARC Press, LyonGoogle Scholar
  8. 8.
    Heitz P, Komminoth P, Perren A et al. (2004) Tumours of endocrine organs. World Health Organisation Classification of Tumors International Agency for Research on Cancer. IARC Press, Lyon.Google Scholar
  9. 9.
    Helpap B, Köllermann J (2001) Immunohistochemical analysis of the proliferative activity of neuroendocrine tumors from various organs. Are there indications for a neuroendocrine tumor-carcinoma sequence? Virchows Arch 438: 86–91PubMedCrossRefGoogle Scholar
  10. 10.
    Soga J (2003) Carcinoid and their variant endocrinomas. An analysis of 11,842 reported cases. J Exp Clin Cancer Res 22: 517–30PubMedGoogle Scholar
  11. 11.
    Travis WD, Rush W, Flieder DB et al. (1998) Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 22: 934–44PubMedCrossRefGoogle Scholar
  12. 12.
    Moran CA, Suster S (2000) Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathological analysis of 80 cases. Am J Clin Pathol 114: 100–10PubMedCrossRefGoogle Scholar
  13. 13.
    Mitry E, Baudin E, Ducreux M et al. (1999) Treatment of poorly-differentiated neuroendocrine tumours with etoposide and cisplatine Br J Cancer 81(8): 1351–5PubMedCrossRefGoogle Scholar
  14. 14.
    Garcia-Yuste M, Matilla JM, Alvarez-Gago T et al. and the EMETNE-SEPRA (2000) Prognostic factors in neuroendocrine lung tumors: a spanish multicenter study. Ann Thorac Surg 70: 258–63PubMedCrossRefGoogle Scholar
  15. 15.
    Takei H, Asamura H, Maeshima A et al. (2002) Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 124: 285–92PubMedCrossRefGoogle Scholar
  16. 16.
    Cardillo G, Dstat FS, Di Martino M et al. (2004) Bronchial carcinoid tumors: nodal status and long-term survival after resection. Ann Thor Surg 77(5): 1781–5CrossRefGoogle Scholar
  17. 17.
    Stinner B, Kisker O, Zielke A et al. (1996) Surgical management of carcinoid tumors of small bowel, appendix, colon, and rectum. W J Surg 20: 183–8CrossRefGoogle Scholar
  18. 18.
    Schindl M, Niederle B, Häfner M et al. (1998) Stage dependant therapy of rectal carcinoid tumors. W J Surg 22: 628–34CrossRefGoogle Scholar
  19. 19.
    Lowney JK, Frisella MM, Lairmore TC et al. (1999) Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary size. Surgery 125: 1043–9Google Scholar
  20. 20.
    Onaitis MW, Kirshbom PM, Hayward TZ et al. (2000) Gastrointestinal carcinoids: characterization by site of origin and hormone production. Ann Surg 232: 549–56PubMedCrossRefGoogle Scholar
  21. 21.
    Shebani KO, Souba WW, Finkelstein DM et al. (1999) Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 29: 815–23CrossRefGoogle Scholar
  22. 22.
    Rindi G, Azzoni C, La Rosa S et al. (1999) ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis Gastroenterology 116: 532–42PubMedCrossRefGoogle Scholar
  23. 23.
    Gullo L, Migliori M, Falconi M et al. (2003) Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study. Am J Gastroenterol 98: 2435–9PubMedCrossRefGoogle Scholar
  24. 24.
    Hoffmann KM, Furukawa M, Jensen RT (2005) Duodenal neuroendocrine tumors: classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol 19: 675–97PubMedCrossRefGoogle Scholar
  25. 25.
    Baudin E, Bidart JM, Rougier P et al. (1999) Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumors. J Clin Endocrinol Metab 84: 69–75PubMedCrossRefGoogle Scholar
  26. 26.
    Pacak K, Ilias I, Chen CC et al. (2004) The role of 18F-fluorodeoxyglucose positron emission tomography and 111I-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing’s syndrome. J Clin Endocrinol Metab 89: 2214–21PubMedCrossRefGoogle Scholar
  27. 27.
    Leboulleux S, Baudin E, Young J et al. (1999) Gastroenteropancreatic neuroendocrine tumor metastases to the thyroid gland: differential diagnosis with medullary thyroid carcinoma. Eur J Endocrinol 140: 187–91PubMedCrossRefGoogle Scholar
  28. 28.
    Sturm N, Lantuejoul S, Laverriere MH et al. (2003) Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34bE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Hum Pathol 32: 918–25CrossRefGoogle Scholar
  29. 29.
    Norheim I, Oberg K, Theodorsson-Norheim E et al. (1987) Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localisation, hormone production, and survival. Ann Surg 206: 115–25PubMedCrossRefGoogle Scholar
  30. 30.
    O’Connor Dt, Deftos LJ (1986) Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 314: 1145–51PubMedGoogle Scholar
  31. 31.
    Baudin E, Dromain C (2002) Biology and imaging of neuroendocrine tumors Rev Prat 52: 268–73PubMedGoogle Scholar
  32. 32.
    Taupenot L, Harper KL, O’Connor DT (2003) The chromogranin-secretogranin family. N Engl J Med 348: 1134–49PubMedCrossRefGoogle Scholar
  33. 33.
    Janson ET, Holmberg L, Stridsberg M et al. (1997) Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 8: 685–90PubMedCrossRefGoogle Scholar
  34. 34.
    Nobels FR, Wekkeboom DJ, Coopmans W et al. (1997) Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the a-subunit of glycoprotein hormones. J Clin Endocrinol Metab 82: 2622–8PubMedCrossRefGoogle Scholar
  35. 35.
    Baudin E, Gigliotti A, Ducreux M et al. (1998) Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 78: 1102–7PubMedGoogle Scholar
  36. 36.
    Bajetta E, Ferrari L, Martineti A et al. (1998) Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyndole acetic acid evaluation in patients with neuroendocrine tumors. Br J Cancer 86: 858–65Google Scholar
  37. 37.
    Nehar D, Lombard-Bohas C, Olivieri S et al. (2004) Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endoc 60: 644–52CrossRefGoogle Scholar
  38. 38.
    Goebel S, Serrano J, Yu F et al. (1999) Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. Cancer 85: 1470–83PubMedCrossRefGoogle Scholar
  39. 39.
    Stivanello M, Berruti A, Torta M et al. (2001) Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Ann Oncol 12: S73–S77PubMedCrossRefGoogle Scholar
  40. 40.
    Stabile BE, Howard TJ, Passaro E et al. (1990) Source of plasma chromogranin A elevation in gastrinoma patients. Arch Surg 125: 451–3PubMedGoogle Scholar
  41. 41.
    Stridsberg M, Oberg K, Li Q et al. (1995) Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 144: 49–59PubMedCrossRefGoogle Scholar
  42. 42.
    Baudin E, Bidart JM, Bachelot A et al. (2001) Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Ann Oncol 12: S79–S82PubMedCrossRefGoogle Scholar
  43. 43.
    Degorce F, Goumon Y, Jacquemart L et al. (1999) A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145–245). Br J Cancer 79: 65–71PubMedCrossRefGoogle Scholar
  44. 44.
    Bender H, Maier A, Wiedenmann B et al. (1992) Immunoluminometric assay of chromogranin A in serum with commercially available reagents. Clin Chem 38: 2267–72PubMedGoogle Scholar
  45. 45.
    Stridsberg M, Eriksson B, Öberg K (2003) A comparison between three commercials kits for chromogranin A measurements. J Endocrinol 177: 337–41PubMedCrossRefGoogle Scholar
  46. 46.
    O’Connor DT, Pandian MR, Carlton E et al. (1989) Rapid radioimmunoassay of circulating chromogranin A: In votro stability, exploration of the neuroendocrine charachter of neoplasia, and assessment of the effects of organ failure. Clin Chem 35: 1631–7PubMedGoogle Scholar
  47. 47.
    Borch K, Stridsberg M, Burman P et al. (1997) Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol 32: 198–202PubMedCrossRefGoogle Scholar
  48. 48.
    Hsiao RJ, Mezger MS, O’Connor DT (1990) Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 37: 955–64PubMedCrossRefGoogle Scholar
  49. 49.
    Giovanella L, Ceriani L, Lumastro C et al. (2007) False-positive serum chromogranin A assay due to heterophile antibody interference. Clin Chim Acta 379: 171–2PubMedCrossRefGoogle Scholar
  50. 50.
    Eriksson B, Arnberg H, Oberg K et al. (1990) A polyclonal antiserum against chromogranin A and B—a new sensitive marker for neuroendocrine tumours. Acta Endocrinol (Copenh) 122: 145–55PubMedGoogle Scholar
  51. 51.
    Dittati R, Meo S, Gion M et al. (2004) Biological variation of plasma chromogranin A. Clin Chem Lab Med 42: 109–10CrossRefGoogle Scholar
  52. 52.
    Eriksson B, Oberg K, Skogseid B (1989) Neuroendorine pancreatic tumors. Clinical findings in a prospective study of 84 patients. Acta Oncol 28: 373–7PubMedCrossRefGoogle Scholar
  53. 53.
    Meijer WG, Kema IP, Volmer M et al. (2000) Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clin Chem 46: 1588–96PubMedGoogle Scholar
  54. 54.
    Panzuto F, Severi C, Canizzaro R et al. (2004) Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Invest 27: 6–11PubMedGoogle Scholar
  55. 55.
    Borch K, Ahren B, Ahlman H et al. (2005) Gastric carcinoids. Biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 242: 64–73PubMedCrossRefGoogle Scholar
  56. 56.
    Brandi ML, Gagel RF, Angeli A et al. (2001). Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endoc Metab 86(12): 5658–71CrossRefGoogle Scholar
  57. 57.
    Hammel P, Vilgrain V, Terris B et al. (2000) Gastroenterology 119(4): 1087–95PubMedCrossRefGoogle Scholar
  58. 58.
    Grandberg D Stridsberg M, Seensalu R et al. (1999) Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 84(8): 2712–7CrossRefGoogle Scholar
  59. 59.
    Bashir S, Gibril F, Ojeaburu JV et al. (2002) Prospective study of the ability of histamine, serotonin or serum chromogranin A levels to identify gastric carcinoids patients with gastrinomas. Aliment Pharmacol Ther 16(7): 1367–82PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France, Paris 2008

Authors and Affiliations

  • É. Baudin
    • 1
  • M. Ducreux
    • 2
    • 3
  • M. d’Herbomez
    • 4
  1. 1.Médecine nucléaire et oncologie endocrinienneInstitut Gustave-RoussyVillejuif Cedex
  2. 2.Service de gastro-entéologie Déartement de médecineInstitut Gustave-RoussyFrance
  3. 3.département de cancérologieHôpital universitaire Paul-BrousseVillejuif Cedex
  4. 4.Clinique Marc LinquetteCHRU de LilleLille Cedex

Personalised recommendations